|Articles|January 15, 2002
- BioPharm International-01-01-2002
- Volume 15
- Issue 1
Information Age Audits
by Joseph F. Noferi, Daniel E. Worden, and Edward R. Arling Understanding the reach of 21 CFR Part 11 is the first step to assessing its impact. To protect your company, you need integrated quality audit solutions to evaluate the underlying validation of your electronic data.
Advertisement
Articles in this issue
about 24 years ago
Inside Washington: Biotechnology in the Limelight, the Year Aheadabout 24 years ago
Your Vested Interests: The War of the Westabout 24 years ago
Statistics for Laboratory Method Comparison Studiesabout 24 years ago
From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continuesabout 24 years ago
Liposomes (a Review): Part Two, Drug Delivery SystemsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5